- Home
- ENTA vs CHRS Comparison
ENTA vs CHRS Comparison
Compare ENTA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- CHRS
- Stock Information
- Founded
- ENTA 1995
- CHRS 2010
- Country
- ENTA United States
- CHRS United States
- Employees
- ENTA N/A
- CHRS N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENTA Health Care
- CHRS Health Care
- Exchange
- ENTA Nasdaq
- CHRS Nasdaq
- Market Cap
- ENTA 112.4M
- CHRS 112.5M
- IPO Year
- ENTA 2013
- CHRS 2014
- Fundamental
- Price
- ENTA $5.93
- CHRS $0.78
- Analyst Decision
- ENTA Buy
- CHRS Buy
- Analyst Count
- ENTA 4
- CHRS 3
- Target Price
- ENTA $17.25
- CHRS $4.68
- AVG Volume (30 Days)
- ENTA 119.2K
- CHRS 1.5M
- Earning Date
- ENTA 05-12-2025
- CHRS 05-12-2025
- Dividend Yield
- ENTA N/A
- CHRS N/A
- EPS Growth
- ENTA N/A
- CHRS N/A
- EPS
- ENTA N/A
- CHRS N/A
- Revenue
- ENTA $64,462,999.00
- CHRS $272,251,000.00
- Revenue This Year
- ENTA N/A
- CHRS N/A
- Revenue Next Year
- ENTA N/A
- CHRS $19.78
- P/E Ratio
- ENTA N/A
- CHRS $1.83
- Revenue Growth
- ENTA N/A
- CHRS 19.87
- 52 Week Low
- ENTA $4.09
- CHRS $0.66
- 52 Week High
- ENTA $17.24
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ENTA 55.39
- CHRS 40.90
- Support Level
- ENTA $5.55
- CHRS $0.74
- Resistance Level
- ENTA $6.23
- CHRS $0.82
- Average True Range (ATR)
- ENTA 0.33
- CHRS 0.07
- MACD
- ENTA 0.05
- CHRS -0.00
- Stochastic Oscillator
- ENTA 75.31
- CHRS 19.71
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.